ArticleBMC cancer2009
Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma.
Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Review
- Review
- Comparative Single-Cell Transcriptomics of Human Neuroblastoma and Preclinical Models Reveals Conservation of an Adrenergic Cell State.Cancer research · 2025Article
- Proinflammatory Macrophage Activation by the Polysialic Acid-Siglec-16 Axis Is Linked to Increased Survival of Patients with Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Cell Adhesion Molecules in Neuroblastoma: Complex Roles, Therapeutic Potential.Frontiers in oncology · 2022Review
- Growth factor signaling predicts therapy resistance mechanisms and defines neuroblastoma subtypes.Oncogene · 2021Article
- Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.BMC systems biology · 2017Article
- 11q deletion in neuroblastoma: a review of biological and clinical implications.Molecular cancer · 2017Review
- Article
- Expression Level of Genes Coding for Cell Adhesion Molecules of Cadherin Group in Colorectal Cancer Patients.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value.American journal of cancer research · 2015Article
- Polysialic acid is associated with better prognosis and IDH1-mutation in diffusely infiltrating astrocytomas.BMC cancer · 2014Article
- Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.Frontiers in oncology · 2014Review
- Reversible adaptive plasticity: a mechanism for neuroblastoma cell heterogeneity and chemo-resistance.Frontiers in oncology · 2012Article
- Cancer vaccines and carbohydrate epitopes.Vaccine · 2011Review
- Article
- Targeting focal adhesion kinase in neuroblastoma.Anti-cancer agents in medicinal chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe expression of a neural crest stem cell marker, polysialic acid (polySia), and its main carrier, neural cell adhesion molecule (NCAM), have been detected in some malignant tumors with high metastatic activity and unfavorable prognosis, but the diagnostic and prognostic value of polySia-NCAM in neuroblastoma is unclear.
methodsA tumor tissue microarray (TMA) of 36 paraffin-embedded neuroblastoma samples was utilized to detect polySia-NCAM expression with a polySia-binding fluorescent fusion protein, and polySia-NCAM expression was compared with clinical stage, age, MYCN amplification status, histology (INPC), and proliferation index (PI).
resultsPolySia-NCAM-positive neuroblastoma patients had more often metastases at diagnosis, and polySia-NCAM expression associated with advanced disease (P = 0.047). Most interestingly, absence of polySia-NCAM-expressing tumor cells in TMA samples, however, was a strong unfavorable prognostic factor for overall survival in advanced disease (P = 0.0004), especially when MYCN was not amplified. PolySia-NCAM-expressing bone marrow metastases were easily detected in smears, aspirates and biopsies.
conclusionPolySia-NCAM appears to be a new clinically significant molecular marker in neuroblastoma, hopefully with additional value in neuroblastoma risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.